5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids

Science Translational Medicine

Volumn 3, Issue 69, 2011, Pages

  Sapieha, Przemyslaw ^a,b   Stahl, Andreas ^a,c   Chen, Jing ^a   Seaward, Molly R ^a   Willett, Keirnan L ^a   Krah, Nathan M ^a   Dennison, Roberta J ^a   Connor, Kip M ^a,i   Aderman, Christopher M ^a   Liclican, Elvira ^d   Carughi, Arianna ^e,f   Perelman, Dalia ^e,f   Kanaoka, Yoshihide ^g   SanGiovanni, John Paul ^h   Gronert, Karsten ^d   Smith, Lois E H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Health Research and Studies Center   (United States)

^f PALO ALTO MEDICAL FOUNDATION   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NATIONAL EYE INSTITUTE   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY DOCOSAHEXAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIETARY INTAKE; ENDOTHELIUM CELL; EYE PROTECTION; HUMAN; LIPID OXIDATION; MALE; METABOLITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTECTION; RETINA NEOVASCULARIZATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; RETINA DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; OXYGEN; PPAR GAMMA; RETINAL DISEASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79851475199     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001571     Document Type: Article

References (64)

1. J. Chen, L. Smith, Retinopathy of prematurity. Angiogenesis 10, 133-140 (2007).
2. P. Sapieha, D. Hamel, Z. Shao, J. C. Rivera, K. Zaniolo, J. S. Joyal, S. Chemtob, Proliferative retinopathies: Angiogenesis that blinds. Int. J. Biochem. Cell Biol. 42, 5-12 (2010).
3. P. Sapieha, J. S. Joyal, J. C. Rivera, E. Kermorvant-Duchemin, F. Sennlaub, P. Hardy, P. Lachapelle, S. Chemtob, Retinopathy of prematurity: Understanding ischemic retinal vasculopathies at an extreme of life. J. Clin. Invest. 120, 3022-3032 (2010).
4. L. E. Smith, Pathogenesis of retinopathy of prematurity. Semin. Neonatol. 8, 469-473 (2003).
5. K. M. Connor, J. P. SanGiovanni, C. Lofqvist, C. M. Aderman, J. Chen, A. Higuchi, S. Hong, E. A. Pravda, S. Majchrzak, D. Carper, A. Hellstrom, J. X. Kang, E. Y. Chew, N. Salem Jr., C. N. Serhan, L. E. Smith, Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13, 868-873 (2007).
6. J. P. SanGiovanni, E. Y. Chew, T. E. Clemons, M. D. Davis, F. L. Ferris III, G. R. Gensler, N. Kurinij, A. S. Lindblad, R. C. Milton, J. M. Seddon, R. D. Sperduto; Age-Related Eye Disease Study Research Group, The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20. Arch. Ophthalmol. 125, 671-679 (2007).
7. M. P. Wymann, R. Schneiter, Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 9, 162-176 (2008).
8. C. N. Serhan, N. Chiang, T. E. Van Dyke, Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349-361 (2008).
9. G. Schmitz, J. Ecker, The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47, 147-155 (2008).
10. J. P. SanGiovanni, E. Y. Chew, The role of ω-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Retin. Eye Res. 24, 87-138 (2005).
11. P. Hardy, M. Beauchamp, F. Sennlaub, F. Gobeil Jr., L. Tremblay, B. Mwaikambo, P. Lachapelle, S. Chemtob, New insights into the retinal circulation: Inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot. Essent. Fatty Acids 72, 301-325 (2005).
12. K. Gronert, Lipid autacoids in inflammation and injury responses: A matter of privilege. Mol. Interv. 8, 28-35 (2008).
13. A. Majos, T. Wolak, P. Bogorodzki, K. Tybor, M. Sapieha, L. Stefańczyk, A blood pool contrast aided T1 functional MRI in patients with brain tumors - a preliminary study. Neuroradiology 10.1007/s00234-010-0809- z (2010).
14. C. D. Funk, Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294, 1871-1875 (2001).
15. C. N. Serhan, Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137 (2007).
16. K. M. Connor, N. M. Krah, R. J. Dennison, C. M. Aderman, J. Chen, K. I. Guerin, P. Sapieha, A. Stahl, K. L. Willett, L. E. Smith, Quantification of oxygen-induced retinopathy in the mouse: A model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565-1573 (2009).
17. A. Stahl, K. M. Connor, P. Sapieha, K. L. Willett, N. M. Krah, R. J. Dennison, J. Chen, K. I. Guerin, L. E. Smith, Computer-aided quantification of retinal neovascularization. Angiogenesis 12, 297-301 (2009).
18. J. X. Kang, J. Wang, L. Wu, Z. B. Kang, Transgenic mice: Fat-1 mice convert n-6 to n-3 fatty acids. Nature 427, 504 (2004).
19. C. N. Serhan, Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot. Essent. Fatty Acids 73, 141-162 (2005).
20. R. C. Murphy, M. A. Gijón, Biosynthesis and metabolism of leukotrienes. Biochem. J. 405, 379-395 (2007).
21. K. F. Austen, The mast cell and the cysteinyl leukotrienes. Novartis Found. Symp. 271, 166-175 (2005).
22. L. G. Letts, Leukotrienes: Role in cardiovascular physiology. Cardiovasc. Clin. 18, 101-113 (1987).
23. E. Osher, G. Weisinger, R. Limor, K. Tordjman, N. Stern, The 5 lipoxygenase system in the vasculature: Emerging role in health and disease. Mol. Cell. Endocrinol. 252, 201-206 (2006).
24. M. Peters-Golden, W. R. Henderson Jr., Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007).
25. R. C. Murphy, R. M. Barkley, K. Zemski Berry, J. Hankin, K. Harrison, C. Johnson, J. Krank, A. McAnoy, C. Uhlson, S. Zarini, Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal. Biochem. 346, 1-42 (2005).
26. A. González-Périz, R. Horrillo, N. Ferré, K. Gronert, B. Dong, E. Morán-Salvador, E. Titos, M. Martínez- Clemente, M. López-Parra, V. Arroyo, J. Clària, Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: A role for resolvins and protectins. FASEB J. 23, 1946-1957 (2009).
27. I. R. Hassan, K. Gronert, Acute changes in dietary ω-3 and ω-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J. Immunol. 182, 3223-3232 (2009).
28. C. N. Serhan, Y. Lu, S. Hong, R. Yang, Mediator lipidomics: Search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol. 432, 275-317 (2007).
29. G. Y. Diau, A. T. Hsieh, E. A. Sarkadi-Nagy, V. Wijendran, P. W. Nathanielsz, J. T. Brenna, The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med. 3, 11 (2005).
30. P. Yli-Jama, H. E. Meyer, J. Ringstad, J. I. Pedersen, Serum free fatty acid pattern and risk of myocardial infarction: A case-control study. J. Intern. Med. 251, 19-28 (2002).
31. T. Itoh, L. Fairall, K. Amin, Y. Inaba, A. Szanto, B. L. Balint, L. Nagy, K. Yamamoto, J. W. Schwabe, Structural basis for the activation of PPARγ by oxidized fatty acids. Nat. Struct. Mol. Biol. 15, 924-931 (2008).
32. A. González-Périz, A. Planagumà, K. Gronert, R. Miquel, M. López-Parra, E. Titos, R. Horrillo, N. Ferré, R. Deulofeu, V. Arroyo, J. Rodés, J. Clària, Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: Protectin D1 and 17S-hydroxy-DHA. FASEB J. 20, 2537-2539 (2006).
33. T. Itoh, K. Yamamoto, Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand. Naunyn Schmiedebergs Arch. Pharmacol. 377, 541-547 (2008).
34. A. Stahl, L. Paschek, G. Martin, N. J. Gross, N. Feltgen, L. L. Hansen, H. T. Agostini, Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett. 582, 3097-3102 (2008).
35. P. Sapieha, M. Sirinyan, D. Hamel, K. Zaniolo, J. S. Joyal, J. H. Cho, J. C. Honoré, E. Kermorvant-Duchemin, D. R. Varma, S. Tremblay, M. Leduc, L. Rihakova, P. Hardy, W. H. Klein, X. Mu, O. Mamer, P. Lachapelle, A. Di Polo, C. Beauséjour, G. Andelfinger, G. Mitchell, F. Sennlaub, S. Chemtob, The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat. Med. 14, 1067-1076 (2008).
36. R. T. Holman, The slow discovery of the importance of ω3 essential fatty acids in human health. J. Nutr. 128, 427S-433S (1998).
37. C. N. Serhan, M. Hamberg, B. Samuelsson, Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U.S.A. 81, 5335-5339 (1984).
38. E. Tjonahen, S. F. Oh, J. Siegelman, S. Elangovan, K. B. Percarpio, S. Hong, M. Arita, C. N. Serhan, Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13, 1193-1202 (2006).
39. N. G. Bazan, Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot. Essent. Fatty Acids 81, 205-211 (2009).
40. N. G. Bazan, Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J. Lipid Res. 50 (Suppl.), S400-S405 (2009).
41. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, S. A. Kliewer, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953-12956 (1995).
42. S. Altiok, M. Xu, B. M. Spiegelman, PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11, 1987-1998 (1997).
43. T. Murata, Y. Hata, T. Ishibashi, S. Kim, W. A. Hsueh, R. E. Law, D. R. Hinton, Response of experimental retinal neovascularization to thiazolidinediones. Arch. Ophthalmol. 119, 709-717 (2001).
44. L. Q. Shen, A. Child, G. M. Weber, J. Folkman, L. P. Aiello, Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol. 126, 793-799 (2008).
45. D. J. Graham, R. Ouellet-Hellstrom, T. E. MaCurdy, F. Ali, C. Sholley, C. Worrall, J. A. Kelman, Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
46. J. H. Lee, J. H. O'Keefe, C. J. Lavie, W. S. Harris, Omega-3 fatty acids: Cardiovascular benefits, sources and sustainability. Nat. Rev. Cardiol. 6, 753-758 (2009).
47. L. E. Smith, E. Wesolowski, A. McLellan, S. K. Kostyk, R. D'Amato, R. Sullivan, P. A. D'Amore, Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101-111 (1994).
48. L. P. Aiello, E. A. Pierce, E. D. Foley, H. Takagi, H. Chen, L. Riddle, N. Ferrara, G. L. King, L. E. Smith, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461 (1995).
49. G. S. Robinson, E. A. Pierce, S. L. Rook, E. Foley, R. Webb, L. E. Smith, Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U.S.A. 93, 4851-4856 (1996).
50. A. P. Adamis, D. T. Shima,M. J. Tolentino, E. S. Gragoudas, N. Ferrara, J. Folkman, P. A. D'Amore, J.W.Miller, Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66-71 (1996).
51. A. Stahl, K. M. Connor, P. Sapieha, J. Chen, R. J. Dennison, N. M. Krah, M. R. Seaward, K. L. Willett, C. M. Aderman, K. I. Guerin, J. Hua, C. Löfqvist, A. Hellström, L. E. Smith, The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 51, 2813-2826 (2010).
52. C. N. Serhan, C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, K. Gronert, Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from ω-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204 (2000).
53. C. N. Serhan, B. D. Levy, C. B. Clish, K. Gronert, N. Chiang, Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: A window for therapeutic opportunity. Ernst Schering Res. Found. Workshop 143-185 (2000).
54. C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, R. L. Moussignac, Resolvins: A family of bioactive products of ω-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
55. S. Hong, K. Gronert, P. R. Devchand, R. L. Moussignac, C. N. Serhan, Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
56. Y. Kanaoka, A. Maekawa, J. F. Penrose, K. F. Austen, B. K. Lam, Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276, 22608-22613 (2001).
57. C. N. Serhan, J. Savill, Resolution of inflammation: The beginning programs the end. Nat. Immunol. 6, 1191-1197 (2005).
58. T. Moriguchi, S. Y. Lim, R. Greiner, W. Lefkowitz, J. Loewke, J. Hoshiba, N. Salem Jr., Effects of an n-3-deficient diet on brain, retina, and liver fatty acyl composition in artificially reared rats. J. Lipid Res. 45, 1437-1445 (2004).
59. L. M. Leesnitzer, D. J. Parks, R. K. Bledsoe, J. E. Cobb, J. L. Collins, T. G. Consler, R. G. Davis, E. A. Hull-Ryde, J. M. Lenhard, L. Patel, K. D. Plunket, J. L. Shenk, J. B. Stimmel, C. Therapontos, T. M. Willson, S. G. Blanchard, Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650 (2002).
60. D. Liu, B. X. Zeng, S. H. Zhang, S. L. Yao, Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm. Res. 54, 464-470 (2005).
61. K. Gronert, C. B. Clish, M. Romano, C. N. Serhan, Transcellular regulation of eicosanoid biosynthesis. Methods Mol. Biol. 120, 119-144 (1999).
62. S. Brault, F. Gobeil Jr., A. Fortier, J. C. Honoré, J. S. Joyal, P. S. Sapieha, A. Kooli, E. Martin, P. Hardy, A. Ribeiro-da-Silva, K. Peri, P. Lachapelle, D. Varma, S. Chemtob, Lysophosphatidic acid induces endothelial cell death by modulating the redox environment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1174-R1183 (2007).
63. T. Korff, H. G. Augustin, Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol. 143, 1341-1352 (1998).
64. -/- mice. P.S., A.S., L.E.H.S., J.C., K.G., M.R.S., K.L.W., N.M.K., R.J.D., C.M.A., and E.L. contributed to the total data analysis for preparation of figures. All authors approved the manuscript. Competing interests: The authors declare that they have no competing interests.